Economic Model Reveals Best Therapies

Published Online: Wednesday, June 1, 2005

A joint study from UCLA and the Veterans Affairs Greater Los Angeles Healthcare System found that the combination of a common nonsteroidal anti-inflammatory drug (NSAID) and an acid-lowering drug is both cost-effective and treatment-effective. The study team compared 3 therapies for treating arthritis: (1) an NSAID, such as ibuprofen or naproxen; (2) an NSAID with an acid-reducer (proton pump inhibitor; PPI), such as lansoprazole (Prevacid) or esomeprazole magnesium (Nexium); and (3) a cyclooxygenase-2 (COX-2) inhibitor, such as rofecoxib (Vioxx) or celecoxib (Celebrex).

The results showed that, for high-risk patients, an OTC NSAID used with a PPI was the safest and most cost-effective treatment. Study author Dr. Brennan Spiegel, codirector of the Center for the Study of Digestive Healthcare Quality and Outcomes, remarked, "COX-2 inhibitors were not a health economic bargain at all-especially given the added costs of more heart attacks."

Latest Articles
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
The FDA has approved Merck’s supplemental new drug application for single-dose fosaprepitant dimeglumine for injection.
Latest Issues